H. Lundbeck A/S of Denmark will substantially broaden its pipeline of central nervous system (CNS) products following the acquisition of the US-based specialty pharmaceutical company, Ovation Pharmaceuticals, Inc.
The all-cash acquisition, which is valued at up to $900 million, was announced on 9 February 2009. It is expected to close in March.